Tirzepatide’s benefits fade for most: Weight and health markers rebound after withdrawal, study finds
Eli Lilly and Company, along with partner institutions in the US and United Kingdom, describe how short-term pharmacologic intervention does not appear to have lasting effects for most tirzepatide patients. People with obesity who lost weight on tirzepatide often regained at least 25% of that loss within a year of stopping treatment, along with reversals in improvements in waist circumference, blood pressure, lipids, and glycemic measures.
The Download: the mysteries surrounding weight-loss drugs, and the economic effects of AI
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. What we still don’t know about weight-loss drugs Weight-loss drugs have been back in the news this week. First, we heard that Eli Lilly, the company behind Mounjaro and Zepbound, became the first […]
Weight-loss drug doesn’t reduce risk of Alzheimer’s – new studies
Vitalii Vodolazskyi/Shutterstock.com Semaglutide, the drug behind the blockbuster weight-loss jabs Ozempic and Wegovy, does not slow cognitive decline in people with early-stage Alzheimer’s, according to two large new studies. The results close the door, for now, on hopes that a treatment for diabetes and obesity might also help protect the brain. The evoke and evoke+ […]
Here’s What is Affected Jack in the Box’s (JACK) Growth Plans
Prosper Stars & Stripes, a long/short equity fund, recently released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the third quarter of 2025, Prosper Stars & Stripes achieved a net return of +9.8%. In comparison, its long/short equity hedge fund peer group, as indicated by the HFRX Equity […]
The Era of Custom Weight-Loss Drugs Is Coming
“Ozempic is about to be old news,” my colleague Yasmin Tayag wrote in 2023, just before an even more powerful obesity drug, tirzepatide, then best known as Mounjaro, was approved. Well, two years later, Mounjaro is becoming old news, too. A whole slew of next-generation obesity drugs are on the horizon, some already advanced enough […]
IJMS, Vol. 26, Pages 11548: From Phytochemistry to Metabolic Regulation: The Insulin-Promoting Effects of Loureirin B Analogous to an Agonist of GLP-1 Receptor
IJMS, Vol. 26, Pages 11548: From Phytochemistry to Metabolic Regulation: The Insulin-Promoting Effects of Loureirin B Analogous to an Agonist of GLP-1 Receptor International Journal of Molecular Sciences doi: 10.3390/ijms262311548 Authors: Haowen Fang Xiaodong Sun Yanting Ding Siyuan Gu Bing Niu Qin Chen This study aimed to develop a potent, safe, and cost-effective small-molecule hypoglycemic […]
Healthcare, Vol. 13, Pages 3102: Exploring Adults’ Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study
Healthcare, Vol. 13, Pages 3102: Exploring Adults’ Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study Healthcare doi: 10.3390/healthcare13233102 Authors: Shukri Adam Fatma M. Ibrahim Eman Abdelaziz Ahmed Dabou Sneha Pitre Rania Aiman Shimaa AbdelSamad Background: Obesity confers substantial cardiometabolic risk. Tirzepatide, a once-weekly dual GIP/GLP-1 receptor agonist, produces dose-dependent weight loss in trials, but […]
Nutrients, Vol. 17, Pages 3735: Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes
Nutrients, Vol. 17, Pages 3735: Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes Nutrients doi: 10.3390/nu17233735 Authors: Isabel Krug An Binh Dang Jade Portingale Yakun Li Ying Qing Won Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed treatment for higher weight and diabetes. Because they also […]
What we still don’t know about weight-loss drugs
Weight-loss drugs have been back in the news this week. First, we heard that Eli Lilly, the company behind the drugs Mounjaro and Zepbound, became the first healthcare company in the world to achieve a trillion-dollar valuation. Those two drugs, which are prescribed for diabetes and obesity respectively, are generating billions of dollars in revenue for […]
Comparative effectiveness of SGLT2 sodium‐glucose cotransporter‐2 inhibitors and GLP‐1 glucagon‐like peptide‐1 receptor agonists for incident dementia: A retrospective multicohort study
Abstract Objective This study provides real-world evidence on the comparative effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) regarding the risk of incident dementia in adults with type 2 diabetes mellitus (T2DM). Research Design and Methods This cohort study utilised electronic health records from TriNetX (1 April 2013 to 31 […]